Jeffrey Walch
Stock Analyst at Bernstein
(2.31)
# 3,096
Out of 5,088 analysts
32
Total ratings
50%
Success rate
3.4%
Average return
Main Sectors:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterated: Hold | $12 | $16.20 | -26.54% | 7 | Oct 26, 2026 | |
| BIIB Biogen | Reiterated: Buy | $236 | $249.65 | -5.47% | 1 | Oct 19, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $376 | $174.00 | +116.09% | 3 | Sep 25, 2026 | |
| BNTX BioNTech SE | Reiterated: Hold | $96 | $89.13 | +7.71% | 4 | Sep 25, 2026 | |
| INCY Incyte | Reiterated: Hold | $104 | $116.80 | -10.96% | 3 | Sep 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $207.83 | +10.19% | 3 | Sep 25, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $218 | $146.38 | +48.93% | 4 | Sep 25, 2026 | |
| RVMD Revolution Medicines | Reiterated: Hold | $179 | $190.27 | -5.92% | 5 | Sep 25, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $608 | $540.00 | +12.59% | 2 | Sep 25, 2026 |
Summit Therapeutics
Oct 26, 2026
Reiterated: Hold
Price Target: $12
Current: $16.20
Upside: -26.54%
Biogen
Oct 19, 2026
Reiterated: Buy
Price Target: $236
Current: $249.65
Upside: -5.47%
Alnylam Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $376
Current: $174.00
Upside: +116.09%
BioNTech SE
Sep 25, 2026
Reiterated: Hold
Price Target: $96
Current: $89.13
Upside: +7.71%
Incyte
Sep 25, 2026
Reiterated: Hold
Price Target: $104
Current: $116.80
Upside: -10.96%
Jazz Pharmaceuticals
Sep 25, 2026
Reiterated: Hold
Price Target: $229
Current: $207.83
Upside: +10.19%
Neurocrine Biosciences
Sep 25, 2026
Reiterated: Buy
Price Target: $218
Current: $146.38
Upside: +48.93%
Revolution Medicines
Sep 25, 2026
Reiterated: Hold
Price Target: $179
Current: $190.27
Upside: -5.92%
Vertex Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $608
Current: $540.00
Upside: +12.59%